Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Orders Pref. Govts to Strengthen Snap Inspections against Drug Makers after Kobayashi Kako Fiasco
February 12, 2021
- Japan Now Sees Fewer Doses per Pfizer Vaccine Vial as Special Syringes Run Short
February 12, 2021
- Incyte’s Pemigatinib Up for PAFSC Review on Feb. 22, March Approval Likely?
February 10, 2021
- LDP Project Team Draws Up Proposal on COVID-19 Vaccination System
February 10, 2021
- New Versions of Trelegy, Lasvic Approved for Listing on Feb. 18
February 10, 2021
- EU OKs Export of 1st Batch of Pfizer’s Coronavirus Vaccines: Minister
February 10, 2021
- Kobayashi Kako Slapped with Record 116-Day Business Suspension
February 9, 2021
- Pfizer’s COVID-19 Shot Up for PAFSC Review Feb. 12, Kono Expects Govt to Secure Enough Doses for 1st-in-Line HCPs
February 9, 2021
- Regulators to Issue Biz Suspension Order to Kobayashi Kako on Feb. 9
February 8, 2021
- MHLW, Saudi Govt Sign Memo on Regulatory Harmonization; Japan-Listed Drugs to Get Priority Review
February 4, 2021
- Drug Pricing Rules to Be Applied to Yescarta: Chuikyo
February 4, 2021
- Celgene’s Liso-Cel Up for PAFSC Review on Feb. 17, 3rd CAR-T Therapy in Japan
February 4, 2021
- New EU Export Regulations Affecting Japan’s Vaccine Supply Schedule: Kono
February 3, 2021
- Japan Moves Up Vaccine Rollout Target to Mid-February, PAFSC Review on Feb. 12?
February 3, 2021
- Japan Govt to Nearly Double Caps for COVID-19 Municipal Grants: Kono
February 2, 2021
- Japan Weighs Workplace Vaccination for COVID-19
February 2, 2021
- MHLW Issues List of Wholesalers Responsible for COVID-19 Vaccine Distribution in Each Region
February 2, 2021
- PMDA Reviewing Safety Risks for NSAIDs, and More Products
February 1, 2021
- Govt Giving Advice to Fujifilm after Shelving Decision on Avigan
February 1, 2021
- PAFSC OKs Seikagaku’s Osteoarthritis Med for Use Excluding Ankle Joints, Bayer’s Larotrectinib Too
February 1, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…